nasdaq:life
|
109867
|
Mar 23rd, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
75.00
|
Open
|
|
Mar 22nd, 2024 11:50PM
|
Mar 23rd, 2024 07:00PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 22nd, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
75.00
|
Open
|
|
Mar 21st, 2024 11:41PM
|
Mar 22nd, 2024 06:48PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 21st, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 20th, 2024 11:54PM
|
Mar 21st, 2024 05:32PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 20th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 20th, 2024 12:31AM
|
Mar 20th, 2024 07:33PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 19th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 18th, 2024 11:29PM
|
Mar 19th, 2024 06:05PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 18th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 17th, 2024 11:51PM
|
Mar 18th, 2024 07:17PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 17th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 17th, 2024 01:31AM
|
Mar 17th, 2024 01:31AM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 16th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 15th, 2024 11:20PM
|
Mar 16th, 2024 07:04PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 15th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 15th, 2024 12:47AM
|
Mar 15th, 2024 08:54AM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:life
|
109867
|
Mar 14th, 2024 12:00AM
|
aTyr Pharma
|
5.2K
|
74.00
|
Open
|
|
Mar 13th, 2024 11:18PM
|
Mar 14th, 2024 12:15PM
|
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
|
Open
|
Biologics, Drug Discovery and Development, Rare and Orphan Diseases, and Autoimmune Diseases
|
Open
|
10240 Sorrento Valley Rd
|
San Diego
|
California
|
US
|
92121
|
|
aTyr Pharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|